Cargando…
Erratum to “Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab”
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436286/ https://www.ncbi.nlm.nih.gov/pubmed/34527081 http://dx.doi.org/10.1177/17588359211047708 |
| _version_ | 1783751969462026240 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8436286 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | SAGE Publications |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84362862021-09-14 Erratum to “Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab” Ther Adv Med Oncol Erratum SAGE Publications 2021-09-11 /pmc/articles/PMC8436286/ /pubmed/34527081 http://dx.doi.org/10.1177/17588359211047708 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| spellingShingle | Erratum Erratum to “Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab” |
| title | Erratum to “Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab” |
| title_full | Erratum to “Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab” |
| title_fullStr | Erratum to “Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab” |
| title_full_unstemmed | Erratum to “Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab” |
| title_short | Erratum to “Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab” |
| title_sort | erratum to “immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab” |
| topic | Erratum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436286/ https://www.ncbi.nlm.nih.gov/pubmed/34527081 http://dx.doi.org/10.1177/17588359211047708 |